[
  {
    "info": {
      "NCT": "NCT05330429",
      "jit": "Optimal",
      "trial_name": "Gilead GS-US-587-6156"
    },
    "disease": {
      "summary": "Metastatic Colorectal Cancer",
      "details": [
        {
          "code": "Mucinous Adenocarcinoma of the Colon and Rectum (MACR)",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT05330429",
      "title": "Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)",
      "current_status": "Recruiting",
      "status_verif_date": "September 2022",
      "last_update_date": "September 8, 2022",
      "trial_hold_status": "open",
      "sponsor": "Gilead Sciences",
      "brief_summary": "The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).",
      "conditions": "Metastatic Colorectal Cancer",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI",
          "drug": "Magrolimab | Bevacizumab | Irinotecan | Fluorouracil | Leucovorin",
          "arm_type": "Experimental",
          "line_of_therapy": "2",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI",
              "Gene": "BRAF",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "V600E",
              "Selection": "include",
              "Function": "Not available",
              "summary": "BRAF V600E Mutation  "
            },
            {
              "cohort": "Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "MSI",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "high",
              "summary": "MSI high  "
            },
            {
              "cohort": "Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "MMR",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "unstable",
              "summary": "MMR unstable  "
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI",
          "drug": "Magrolimab | Bevacizumab | Irinotecan | Fluorouracil | Leucovorin",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "Not available",
          "biomarker": [
            {}
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Randomized Cohort: Bevacizumab + FOLFIRI",
          "drug": "Bevacizumab | Irinotecan | Fluorouracil | Leucovorin | NA",
          "arm_type": "Active Comparator",
          "line_of_therapy": "Not available",
          "arm_hold_status": "Not available",
          "biomarker": [
            {}
          ]
        }
      ],
      "docs": "<a href=\\Q:/MCK/MOA/Precision Oncology/JIT Trials/Optimal_Working list Optimal Unblinded Study List_FINAL_draft_2022.08.11.pdf\\target=\"_blank\">site-documentation<\/a>",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT05330429\" target=\"_blank\">NCT05330429<\/a>"
    }
  }
]
